Children's Oncology Group's 2023 blueprint for research: Soft tissue sarcomas.

Autor: Oberoi S; Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.; Department of Pediatric Hematology-Oncology, CancerCare Manitoba, Winnipeg, Manitoba, Canada., Crane JN; Department of Pediatrics, Stanford University, Stanford, California, USA., Haduong JH; Division of Oncology, Hyundai Cancer Institute, Children's Hospital Orange County, Orange, California, USA., Rudzinski ER; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Laboratories, Seattle Children's Hospital, Seattle, Washington, USA., Wolden SL; Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA., Dasgupta R; Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA., Linardic CM; Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Pharmacology & Cancer Biology, Duke University School of Medicine, Durham, North Carolina, USA., Weiss AR; Department of Pediatrics, Maine Medical Center, Portland, Maine, USA., Venkatramani R; Division of Hematology/Oncology, Department of Pediatrics, Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
Jazyk: angličtina
Zdroj: Pediatric blood & cancer [Pediatr Blood Cancer] 2023 Sep; Vol. 70 Suppl 6, pp. e30556. Date of Electronic Publication: 2023 Jul 10.
DOI: 10.1002/pbc.30556
Abstrakt: In the United States, approximately 850-900 children and adolescents each year are diagnosed with soft tissue sarcomas (STS). STS are divided into rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma STS (NRSTS). RMS and NRSTS are risk stratified into low-, intermediate-, and high-risk categories, with 5-year survival rates of approximately 90%, 50%-70%, and 20%, respectively. Recent key achievements from the Children's Oncology Group (COG) STS Committee include the identification of new molecular prognostic factors for RMS, development and validation of a novel risk stratification system for NRSTS, successful completion of a collaborative NRSTS clinical trial with adult oncology consortia, and collaborative development of the INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT). Current COG trials for RMS are prospectively evaluating a new risk stratification system that incorporates molecular findings, de-intensification of therapy for a very low-risk subgroup, and augmented therapy approaches for intermediate- and high-risk RMS. Trials for NRSTS exploring novel targets and local control modalities are in development.
(© 2023 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: